A device to improve immunotherapy delivery for liver cancer treatment
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma
['FUNDING_R37'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11031362
This study is testing a new device called the ImFusion system that helps deliver cancer-fighting treatments directly into liver tumors while also warming the area to boost the treatment's effectiveness, aiming to provide a better and safer option for people with advanced liver cancer.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11031362 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy for advanced hepatocellular carcinoma (HCC) by developing a novel device called the ImFusion system. This device allows for precise intratumoral delivery of immunotherapies while also generating localized hyperthermia to improve treatment outcomes. By overcoming barriers associated with traditional injection methods, the ImFusion system aims to activate the immune response against tumors more effectively. Patients may benefit from a more targeted and efficient treatment approach that minimizes side effects and maximizes therapeutic impact.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced hepatocellular carcinoma who are seeking innovative treatment options.
Not a fit: Patients with early-stage liver cancer or those who do not have hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with advanced liver cancer.
How similar studies have performed: Previous research has shown promising results with localized immunotherapy approaches, suggesting potential for success with this novel delivery system.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHETH, RAHUL ANIL — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: SHETH, RAHUL ANIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Cancer Cause, Cancer Etiology, cancer immunity, cancer metastasis